drugset / Trial / NCT03786757

Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)

NCT03786757

Phase 3 Unknown 200 enrolled RenJi Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events. This study aims to assess the efficacy and safety outcomes of Rivaroxaban on the prevention of post-STEMI left ventricular thrombus.

Timeline

Start
2019-04-01
Primary completion
2022-03-30
Completion
2022-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 2.5 mg